Aim: The adequacy of 50 mcg folic acid supplementation given to low-birth-weight babies was investigated. The folate levels of the mothers and infants, and breastmilk, and the optimum dose for folic acid supplementation were also investigated.
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Introduction
Folate is a water-soluble vitamin that cannot be synthesized in the human body. Co-enzymes that contain folate are involved in cell renewal/differentiation, DNA synthesis, methionine synthesis, and hematopoesis. The folate balance in the body depends on intake, destruction, and excretion in urine and stool. If not received regularly, folate deficiency occurs in 2-3 months. Folate deficiency leads to megaloblastic anemia (1) .
The erythrocyte folate level (RBCFL) is higher in preterm and term babies compared with adults because fetal folate transfer is increased in pregnancy (especially in the third trimester) (2) (3) (4) (5) . Folate decreases gradually in the first months of life, predominantly in low-birth-weight (LBW) babies. In this rapid growth period of life, requirement of folic acid (FA) increases and the risk of development of folate deficiency is increased. Studies conducted in the 1970s-80s reported that folate levels in preterm babies decreased in the first 2-3 months of life (3, 4) . Therefore, routine FA supplementation was recommended for all preterm babies in the 1990s (6) . In addition to preterm babies, FA supplementation of 20-50 µcg/day was recommended for babies with a birth weight of <2 500 g (7, 8) . In our unit, FA supplementation of 20-50 µcg/day is given to LBW babies. However, the folate levels of the babies were not considered when proposing this recommendation. The mode of feeding for the baby [breastmilk (BM), formula, fortified breastmilk (FBM) or total parenteral nutrition] and/or the folate level of the baby at the time of birth affects the requirement for folate. Unfortunately, there are a limited number of studies related with normal blood folate levels in the neonatal period comprising heterogeneous groups (9) .
Owing to the inadequacy of the current information related with FA supplementation dose and its necessity in low-birthweight babies, the following questions were investigated: 
Material and Methods
After written informed consent was obtained from the families, LBW babies who were born in Ondokuz Mayıs University (OMU) Hospital between 01.01.2012 and 09.31.2012 and followed up in the neonatal intensive care unit (NICU) were included in this prospective study. Blood samples were obtained from the babies after admission in the ward for serum/ RBCFL and hematocrit levels. Afterwards, the babies were divided into three groups using a sealed tender and accordingly given 25 µcg, 50 µcg, and 75 µcg FA supplementation daily. The prenatal, natal, and postnatal characteristics of the babies were recorded. The modes of daily feeding (BM and/or formula, SBM) and the amount of FA supplementation were recorded. Folic acid supplementation was discontinued when the baby became 2 500 g or one month of age (whichever occured first). At the end of supplementation, blood samples were obtained from the babies for follow-up serum/RBCFL and hematocrit values. Blood samples from the mothers for serum/RBCFL and hematocrit values were obtained in the first 48 hours in the postnatal period. The samples for BM folate levels were obtained in the first 72 hours. Prenatal maternal FA intake was recorded.
According to the protocol applied in our unit, BM fortifier was initiated when the baby was receiving 50 mL/kg BM. Breastmilk fortifier was prepared by adding 3 spoons of BM fortifier (Eoprotin) into 100 mL BM. The fortified BM contains 50 μg/100 mL FA and the preterm formula used in our unit (Prematil) contains 28 μg/100 mL FA.
Ethics committee approval was obtained for the study (Number: 2011/339) and financial support was obtained from Ondokuz Mayıs University (PYO.TIP.1904.11.032). Financial support was obtained from the drug company Berko for studying BM folate levels.
Biochemical Tests
In our study, RBCFL was also studied in addition to folate level because studies have reported that RBCFL gives better information about body stores (10) . The samples were placed in regular tubes and K3-EDTA tubes. The samples in the regular tubes were centrifuged for 5 minutes at 3000 g and kept in polystyrene tubes at -50°C. No procedure was applied for the samples placed in K 3 -EDTA tubes and they were kept at -50°C.
For measurement of the total blood folate level, 0.2% ascorbic acid solution was prepared to disintegrate the erythrocytes inside the K 3 -EDTA tubes. For preparation of 0.2% ascorbic acid, one bag among the 0.4 g ascorbic acid bags in the ROCHE RBC Folate Hemolyzing kit was poured into the 200 mL plastic container found in the same kit. Deionized water (200 mL) was added to the container and mixed after waiting for 5 minutes at room temperature.
Three milliliters of 0.2% ascorbic acid solution was placed in 5 mL polystyrene tubes. After it was dissolved at room temperature and mixed by reversing, 100 microliters were removed from the blood in the K 3 -EDTA tube and added to the prepared ascorbic acid solution. After these tubes were reversed three times, they were incubated at room temperature for 90±15 minutes. The RBCFL was measured for disintegration of the erythrocytes. The complete blood folate level was studied using competitive electrochemiluminescence immunoassay (ECLIA) with the Modular Analytics E170 device. The following formula was used for measurement of ERBC folate level: RBCFL = (folate concentration measured x 31 / % Hematocrit) x 100 A value of >140 ng/mL was considered normal for RBCFL (10) . For analysis of serum folate level, the frozen samples were dissolved at room temperature and measurements were performed using competitive ECLIA with a Modular Analytics E170 device. As in previous studies, a value of <3 ng/mL was considered the limit value for folate deficiency (11, 12) .
The lipid in BM was eliminated to measure the BM folate concentration. The "Extraction of the Lipemic Serum Samples with Chloroform" protocol used in lipemic serum samples was applied. With this objective, 600 µL chloroform was mixed with 300 µL BM and vortexed for one minute. Afterwards, it was centrifuged for 5 minutes at 4°C and 16 000 g. The supernatant was removed and 1/dilution was performed with diluent universal. Folate measurement was performed using copetitive chemiluminescence with a Modular Analytics E 170 device.
Statistical analysis
Statistical analyses were performed using the Statistical Package for the Social Sciences version 15.0 (SPSS Inc.; Chicago, IL, USA). The frequencies in the groups were selected as 46, 46, and 46 with a 95% strength at a confidence interval of 95% such that d=5 difference was found with 6 deviations. Data obtained through measurements are expressed as mean±SD and data obtained by counting are expressed as percentage. The variables did not all show normal distribution. Therefore, nonparametric tests were used in all hypothesis tests. The Wilcoxon signedrank test was used in the comparison of basal values with the control values. Based on these differences, the Kruskal-Wallis test was used to determine whether the changes in the groups were significant. Non-parametric Spearman correlation coefficients were used for correlation measurements. Correlations were calculated for all groups by excluding the groups one by one and for each group separately. The Mann-Whitney U test was used in comparison by intake of folic acid in pregnancy.
In the comparison of categorical variables between the groups, Fischer's exact test and the Chi-square test were used. A p value of <0.05 was considered significant.
Results
One hundred ninety-four LBW babies were followed up in the NICU during the study period. Thirteen babies were excluded from the study and 19 babies were lost. Four babies were excluded because of Down syndrome, eight babies were excluded because of major congenital anomalies, and one baby was excluded because of epidermolysis bullosa. One hundred sixty-two babies were eligible for the study; 18 babies could not be included in the study because their families did not give consent. One baby was not present for a follow-up visit and thus a blood sample could not be obtained from this baby. The blood tubes of two babies were broken. In total, 141 LBW babies were included in the study. The prenatal, natal, and postnatal characteristics of the babies were recorded. After randomization, 46 babies received 25 µcg FA supplementation (group 1), 39 babies received 50 µcg FA supplementation (group 2), and 44 babies received 75 µcg/g FA supplementation (group 3). A control group was not planned because a group that would not receive FA would not be ethical. However, 12 babies could not receive folic acid because of enteral feeding problem. There were nine twins and one set of triplets (130 mothers). A nutrition questionnaire related with nutrition during pregnancy was given to the mothers and all mothers reported that they ate folate-rich food during pregnancy. None of the mothers used alcohol or smoked. The characteristics of the babies, folate levels at birth, maternal characteristics, maternal serum FA levels, RBCFLs, and BM folate levels are shown in Table 1 and 2. The modes of nutrition of the babies were as follows: BM alone 10.6%, BM plus formula 60.9%, FBM 8.2%, formula alone 5.8%, and FBM alone 14.5%. There was no diffference in terms of nutrition mode between the three groups (p=0.058).
The serum folate levels were <3 ng/mL in four mothers and >3 ng/mL in all babies. The RBCFLs were found normal in all mothers including those with low serum folate levels. None of the mothers were diagnosed as having folate deficiency.
A weak statistically significant positive correlation was found between maternal RBCFL and maternal serum folate level (p<0.001, r 2 =14.5%).
A weak statistically significant positive correlation was found between maternal RBCFL and basal neonatal RBCFL (p<0.001, r 2 =15.4).
A weak statistically significant positive correlation was found between maternal RBCFL and the basal neonatal serum folate level (p=0.012, r 2 =3.6%).
No statistically significant correlation was found between the maternal RBCFL and BM folate levels (p=0.366).
No statistically significant correlation was found between the maternal serum folate level and basal neonatal RBCFL (p=0.206).
A weak statistically significant positive correlation was found between the maternal folate level and the basal neonatal serum folate level (p<0.001, r 2 =17.3%). A weak statistically significant positive correlation was found between the maternal serum folate level and BM folate level (p=0.009, r 2 =3.9%).
There was no significant correlation between the maternal RBCFL, maternal serum folate level, and the birth weights of the babies (p=0.466 for RBCFL, p=0.625 for serum) and prenatal delivery (p=0.967 for RBCFL, p=0.651 for serum).
No significant correlation was found between the use of FA in pregnancy and the basal neonatal RBCFL and basal neonatal serum level (p=0.511 for RBCFL, p=0.398 for serum).
The BM folate levels were found statistically significantly higher in mothers who used FA during pregnancy compared with those who used no FA during pregnancy (p<0.001, Figure 1 ).
Although the RBCFL and serum folate levels of the preeclamptic mothers were found lower compared with those who were not preeclamptic, the difference was not statistically significant (p=0.758 for RBCFL, p=0.638 for serum).
No significant correlation was found between the basal neonatal RBCFL and basal neonatal serum folate levels and gestational week, birth weight, respiratory distress syndrome, bronchopulmonary displasia, retinopathy of prematurity, intraventricular hemorrhage, culture positive sepsis, congenital heart disease or rehospitalization for erythrocyte transfusion (p>0.05 for all variables).
There was no difference between the groups that received different doses of FA supplementation in terms of demographic properties (Tables 1 and 2 ). There was also no difference between the three groups in terms of maternal RBCFL, serum, basal neonatal RBCFL, serum or BM folate level (Table 1) .
No statistically significant difference was found between babies who received different doses of FA supplementation in terms of basal serum folate levels (p=0.965).
In all three groups that were given folic acid, the follow-up serum folate levels were found higher compared with basal levels, but there was no difference between the groups (p=0.354) ( Table 3) .
No difference was found between the groups in terms of rehospitalization for erythrocyte transfusion (p=0.638).
No significant correlation was found between the mode of feeding and follow-up serum folate levels (p=0.753).
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Discussion
In this study, the requirement for FA supplementation was investigated in LBW babies. In one study, 29 LBW babies were examined and the mean RBCFL level was found as 563 ng/mL (range, 230-1250 ng/mL) and the mean plasma folate level of 18 babies was reported as 18.7 ng/mL (range, 5.5-30 ng/mL) (13) . In our study, the mean RBCFL and serum folate levels on the first day of life were 922.7±460.7 ng/mL and 21.2±12.2 ng/mL, respectively. The basal RBCFL and serum folate levels were not low in any babies. In a study conducted in Turkey, the mean serum folate level was reported as 11.5-71.7 ng/mL in 162 babies with a gestational age of ≤ 32 weeks (14) . The serum folate and RBCFL levels in the study
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Turk Pediatri Ars 2016; 51: 210-6 Çakmak Çelik et al. Folic acid supplementation for low-birth-weight babies In a study conducted with 35 babies who were fed with BM, preterm babies who received 65 µg/g FA supplementation were compared with preterm babies who did not receive FA supplementation and the RBCFL levels were reported lower in those who did not receive FA supplementation. The mean RBCFL level was reported as 257.4±31.3 ng/mL in the group that received FA supplementation. In the same study, it was reported that RBCFL and plasma folate levels were reported higher in babies compared with adults; none of the mothers used FA during pregnancy (3). In our study, the follow-up serum folate levels of babies who received FA supplementation were found high in each group, but there was no difference between the groups. When more exogeneous FA is received than is required by the body, urinary excretion is increased and excess FA is eliminated from the body. The results of our study suggest that this mechanism is also developed in LBW newborns.
In our study, the follow-up serum and RBCFL levels in 12 babies who did not receive FA supplementation were found as 32.8±34.5 ng/mL and 1054.4±395 ng/mL, respectively. As in the other groups that did not receive folic acid supplementation, FA deficiency did not develop at the end of the first month in the group that did not receive FA.
In a study conducted in 1966, it was reported that the RBCFL levels of babies were higher than their mothers (15) . In our study, the RBCFL and serum folate levels of the babies were found higher compared with their mothers, in aggreement with the study conducted in 1966.
One of the questions that we tried to answer in our study was as follows: What are the maternal RBCFL, serum, and BM folate levels in the 2010s? The maternal serum and RBCFL levels were found as 12.3±7.5 ng/mL and 845.5±301.4 ng/mL, respectively. Folate deficiency was not found in any mother.
Ramasastri (16) In another study, in which folate was studied in maternal BM samples obtained from 20 mothers who received 3.4 mg/day FA starting from the beginning of pregnancy, the BM folate level was reported as 0.3-3.9 ng/mL (13). In our study, the mean BM folate level (considered colostrum, because it was obtained in the first three days) was found as 30.6±33.0 ng/ mL (range, 4.6-165.6 ng/mL) (medan 17 ng/mL). The fact that the maternal BM folate was found higher compared with the other studies may be related with alterations in nutritional behaviors of mothers in the intervening forty-year period. In addition, a weak correlation was observed between the use of FA in pregnancy and maternal folate levels in our study. Therefore, maternal BM folate might have been found higher compared with the other studies. In the study conducted by Tamura et al. (18) , BM folate in 16 mothers was reported as 62-280 ng/mL and it was found that the serum folate level of the baby and folate levels in maternal BM were correlated. However; the authors did not specify which day the BM was obtained. In our study, no correlation was found between maternal BM folate and the follow-up serum folate of the baby.
In a study of 91 mothers, no significant correlation was found between maternal BM folate and the mother's RBC-FL and plasma folate at any stage of lactation (19) . Similarly, we found no correlation between maternal RBCFL and BM folate, but there was a weak statistically significant positive correlation between maternal serum folate and BM folate.
In two studies in which babies fed with preterm formula or FBM were evaluated in terms of FA supplementation, it was reported that these babies did not require FA supplementation (14, 20) .
In our study, no significant difference was found between the groups in terms of the follow-up serum folate level according to feeding mode. The FA supplementation requirement of the babies who were fed with BM alone could not be evaluated in our study because we had no control group with BM feeding alone without FA supplementation.
With this study, it can be stated that the dosage of 25 mc/g is adequate for FA supplementation. In conclusion, the mode of feeding of the baby should be considered when specifying the need for FA supplementation in babies with a weight <2500 g. FA supplementation may not be needed in LBW babies fed with fortified BM or preterm formula and in babies of mothers who have a balanced diet and received folic acid supplementation during pregnancy. Further studies are needed to determine the necessity of FA supplementation in LBW babies who are exclusively fed with BM.
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